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mutation. There was no gender difference in ER expression. The 
survival time for patients with the ER mutation was longer (median 
survival time 44.5 months versus 23.5 months), however these differ-
ences were not statistically signiﬁcant. 
Conclusions: There were strong correlation between ERβ and ERCC1 
expression. These expressions may play a role simultaneously in the 
development of adenocarcinoma of the lung.
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Introduction: Epigenetic alterations in certain genes are now known 
as at least important as genetic mutation in pathogenesis of cancer. 
Especially abnormal promotor region methylation in tumor suppressor 
genes is known to result in gene silencing and therefore loss of gene 
function. Objective We, the authors, wanted to search for new lung 
cancer-speciﬁc tumor suppressor genes through the study, and to ﬁgure 
out the roll of known tumor suppressor genes of other kinds of cancer 
for NSCLC as well. 
Material and Methods: Cancer tissue & adjacent normal tissue were 
obtained from 10 patients who diagnosed with NSCLC and underwent 
surgery in Konyang university hospital in 2005. NotI-MseI Methyla-
tion chip was used to analyze DNA methylation on promoter region of 
27 genes in tumor tissue & nearby normally-appearing tissue. The rate 
of methylation was measured and compared for both groups to ﬁnd 
out the genes associated with tomorigenesis. Also the patients were 
grouped by age, gender, history of smoking, and cell type of NSCLC, 
and compared between groups. And as normal control group we ob-
tained lung tissue from two young patients with pneumothorax during 
their bullectomies, methylations were examinated in the same way and 
compared with tumor and non-tumor tissue from NSCLC patients. 
Result: Among the 27 genes, the higher rate of methylation for tumor 
tissue than that of non-tumor tissue were observed in 14 genes, and 6 
genes including AR, HTR1B, CFTR from those 14 genes in normal 
lung tissue were not methylated, suggesting the possibility of the role 
for TSG(tumor suppressor gene) of NSCLC.
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Background: KILLER/DR5 is a recently identiﬁed p53-regulated 
death recpetor gene that was induced by doxorubicine only in cells with 
wild-type p53 status. KILLER gene was also independently identiﬁed 
as a TRAIL (TNF-related Apoptosis-inducing Ligand) death receptor, 
DR5. KILLER/DR5 is now considered as one of the p53-dependent 
apoptotic genes such as fas, bax, or insulin-like growth factor-binding 
protein 3. However, examination of KILLER/DR5 in primary tumour 
tissue has not yet been reported. In this study, we demonstrate that 
KILLER/DR5 expression is dependent on wild-type p53 status in non-
small cell lung cancer (NSCLC). 
Methods and Materials: Immunohistochemical analysis using the 
avidin-biotinylated horseradish peroxidase complex was carried out in 
eighty-nine surgically resected NSCLC formalin-ﬁxed parafﬁn-embed-
ded tissue sections. As primary antibodies, we used anti-DR5 poly-
clonal antibody (Pro Sci Inc., Poway, CA) and anti-p53 monoclonal 
antibody (DO-7, Novocastra, Inc, Manhasset, NY). A negative control 
was processed with each slide; it excluded the primary antibody but in-
cluded all other steps of the procedure. Positive tumor cells were quan-
tiﬁed twice, expressed as a percentage of the total number of tumor 
cells, and the intensity of immunostaining: 1+, weak and diffuse(>50%) 
or focal (<50%) or moderate and focal; 2+, strong and focal or moder-
ate and diffuse; 3+, strong and diffuse. The analysis of DR5 expression 
was done separately in tumor area and regional normal area. 
Results: DR5 expression was high ( > 2+) in bronchial epithelium 
(89% of cases) but almost absent in type I & II pneumocytes, lympho-
cytes, and smooth muscle cells. High DR5 expression rate in tumor was 
28% (15/53) in squamous cell carcinoma, 47%(15/32) in adenocarci-
noma, and 50% (2/4) in large cell carcinoma, overall 36%. DR5 expres-
sion did not show any statistical signiﬁcance with T stage, N stage, 
and survival. However, DR5 expressiont showed signiﬁcant inverse 
correlation with p53 expression. (p < 0.01). If p53 expression was high, 
there was no expression in DR5 and vice versa. 
Conclusions: This signiﬁcant in vivo correlation between p53 expres-
sion and KILLER/DR5 expression is highly suggestive for the fact that 
KILLER/DR5 is one of important p53-dependent apoptotic genes.
P3-010 BSTB: Molecular Pathology Posters, Wed, Sept 5 – Thur, Sept 6 
Using immunohistochemistry to evaluate protein expression levels 
of female sex hormone receptors (ER, PR) and epidermal growth 
factor receptor family members (EGFR, HER2) in East Asian non-
small cell lung cancers (NSCLC)
Nga, Min En1 Mohd Omar, Mohd Feroz2 Lim, Diana G.1 Lim, Darren3 
Toh, Chee Keong3 Soong, Richie2 Salto Tellez, Manuel2  
Lim, Elaine H.2 
1 National University Hospital, Singapore, 2 National University of 
Singapore, Singapore, 3 National Cancer Centre, Singapore, 
Background: The non-smoking East Asian female with lung adenocar-
cinoma is a phenotype that has been correlated with higher frequencies 
of EGFR mutations, with corresponding increased tumor response to 
tyrosine kinase inhibitors. We hypothesize that estrogen receptor (ER) 
has a role in the biological mechanism underlying this clinical entity, in 
a combinatorial fashion with other signaling transduction components. 
Here, we examine the protein expression levels via immunohistochem-
istry of isoforms of ER, namely ERα and ERβ, progesterone receptor 
(PR), EGFR and HER2.
Methods: Tissue microarrays (TMA): These were constructed from 
parafﬁn-embedded blocks of surgically resected tissues. Each array was 
targeted to contain replicates of 33 adenocarcinomas and 16 squamous 
cell carcinomas, of which 26 and 2 had matched normal lung tissues, 
respectively. 
Immunohistochemistry: Commercially available antibodies identify-
ing ERα, ERβ, PR, EGFR and HER2 were used for staining and detec-
tion, according to the manufacturers’ protocols. The ER, PR and HER2 
analyses used breast invasive ductal carcinomas as positive controls. 
Extent (% of cells) and intensity of staining were scored on a scale of 
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0-3. For ER, PR and EGFR, 0 was scored as ‘negative’; for HER2, 0-1 
was scored as ‘negative’.
Statistical Analyses: Wilcoxon-signed rank (WSR) test was used to 
assess differences between matched samples. Fisher’s exact test and χ2 
analysis were used to assess the correlations between various parameters.
Results:
Table 1: Comparing ERα, ERβ, PR, HER2 protein levels between tumors and 
matched normals. Analysis is by WSR test.
Protein n Expression in Tumor p value
ERa 26 Higher <0.001
ERb 22 No diﬀerence 0.739
PR 26 No diﬀerence 0.739
HER2 27 Higher 0.005
Table 2: Correlation of female gender with various parameters: histological 
subtype and diﬀerentiation, ERα, ERβ, PR, EGFR, HER2 status. Analysis is by 
χ2 test; * = Fisher’s exact test.
Parameter n Female p value
Adenocarcinoma 33 14 (42%)  
Squamous Cell Carcinoma 16 1 (6%) 0.018*
Well Diﬀerentiated 6 4 (67%)  
Moderately Diﬀerentiated 27 6 (22%)  
Poorly Diﬀerentiated 16 5 (31%) 0.102
ERa negative 17 6 (35%)  
ERa positive 32 9 (28%) 0.747*
ERb negative 18 8 (44%)  
ERb positive 30 6 (20%) 0.103*
PR negative 6 2 (33%)  
PR positive 43 13 (30%) >0.999*
HER2 negative 40 10 (25%)  
HER2 positive 9 5 (56%) 0.110*
EGFR negative 31 7 (23%)  
EGFR positive 18 8 (44%) 0.124*
Conclusions: In this series of 49 tumors, there appears to be overex-
pression of ERα and HER2 in NSCLC, compared with matched normal 
tissues. Female NSCLC seems to be more frequently associated with 
adenocarcinoma subtype, with a trend towards well-differentiated 
tumors, ERβ downregulation, EGFR and HER2 overexpression. Addi-
tional work is required to further verify and expand upon these results.
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Background: To determine any phenotype differences between males 
and females with non-smoking lung adenocarcinoma and the presence 
of human papillomavirus (HPV) and Epstein-Barr virus (EBV) in such 
a population.
Materials and Methods: Patients with non-smoking adenocarcinoma 
of the lung were analysed from a case series database of patients 
from 1999 to 2002 in the National Cancer Centre Singapore. Associa-
tion between categorical factors and gender was analysed by Pearson 
chi-squared of Fisher’s exact test. Kaplan-Meier method was used to 
estimate the survival function and log-rank statistic test was used to test 
for survival difference between male and female within each level of 
factor. A P-value of less than 0.05 was considered statistically signiﬁcant 
for all statistical tests. All analyses were performed using SPSS 11.5 for 
Windows. Presence of human papillomavirus and Epstein-Barr Virus 
was tested using the Ventana Benchmark INFORM system (Ventana 
Medical Systems, Tucson, Az, USA) consisting of probes: HPV Family 
16 (HPV genotypes 16, 18, 31, 33, 35, 39, 51, 52, 56, 58, and 66) and 
HPV 6 (HPV genotypes 6 and 11) and EBER (Epstein-Barr early RNA). 
Results: Two hundred patients were analyzed. The ratio of females to 
males was 2.8:1. Patient demographics were compared between sexes 
and there were no signiﬁcant differences between males and females in 
terms of comorbidities, performance status at presentation, or stage of 
presentation at diagnosis. About two-thirds of patients were metastatic 
at diagnosis in both sexes. Both sexes had also similar sites of distant 
metastases at presentation. The survival functions between males and 
females were not signiﬁcantly different from each other within each 
level of a factor except for those who had best supportive care (support-
ive / no treatment) or surgery. It appeared that females tend to survive 
longer than male when they were on best supportive care (P = 0.026). 
Also females seemed to have longer median survival time (69 months) 
compare to males (38 months) if they had surgery. However, the dif-
ference is quite weak, with a P-value of 0.059. Out of the two hundred 
patients for clinical analysis, only 44 (22%) tissue specimens of suf-
ﬁcient quality were suitable for in-situ hybridization methods. Of these 
9 (20%) were males and 35 (80%) from females. There was absence 
of HPV and EBV by in-situ hybridization in all the tumor specimens 
examined. 
Conclusions: There are no signiﬁcant differences in the clinical course 
and phenotypic characteristics of non-smoking adenocarcinoma of 
the lung between sexes. It is likely that non-smoking adenocarcinoma 
constitute a biologically independent subset of NSCLC that does not 
depend on sex. The absence of EBV and HPV in the tumor specimens 
examined here suggest that in certain populations, there is a low likeli-
hood that these viruses are likely to be causative for lung cancer.
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